Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Teva
Fish and Richardson
US Department of Justice
Johnson and Johnson
Colorcon
Novartis
McKesson
UBS
Argus Health

Generated: December 11, 2017

DrugPatentWatch Database Preview

FABIOR Drug Profile

« Back to Dashboard

Which patents cover Fabior, and what generic alternatives are available?

Fabior is a drug marketed by Mayne Pharma and is included in one NDA. There is one patent protecting this drug.

This drug has nineteen patent family members in thirteen countries and three supplementary protection certificates in three countries.

The generic ingredient in FABIOR is tazarotene. There are eight drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the tazarotene profile page.
Drug patent expirations by year for FABIOR

Pharmacology for FABIOR

Ingredient-typeRetinoids
Drug ClassRetinoid

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Mayne PharmaFABIORtazaroteneAEROSOL, FOAM;TOPICAL202428-001May 11, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FABIOR

Country Document Number Estimated Expiration
Canada2753497► Subscribe
South Africa201105769► Subscribe
Eurasian Patent Organization201171079► Subscribe
Japan6182191► Subscribe
China102438590► Subscribe
Mexico2011008912► Subscribe
Singapore173563► Subscribe
BrazilPI1008037► Subscribe
Japan2012518662► Subscribe
World Intellectual Property Organization (WIPO)2010096868► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FABIOR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0008Belgium► SubscribePRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203
/1998Austria► SubscribePRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: 1-22102, 1-22103 19970918; FIRST REGISTRATION: DE 37393.00.00, 37393.01.00 19961203
C/GB98/002United Kingdom► SubscribePRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Merck
Daiichi Sankyo
Novartis
UBS
Chinese Patent Office
Mallinckrodt
McKesson
Federal Trade Commission
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot